SAN DIEGO, Sept. 7, 2010 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Morgan Stanley Global Healthcare Conference on Monday, September 13, 2010 at 10:55 a.m. ET / 7:55 a.m. PT in New York, and at the Baird Global Healthcare Conference on Tuesday, September 14, 2010 at 11:30 a.m. ET / 8:30 a.m. PT in New York. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview at the Morgan Stanley conference. Alex Casdin, vice president, finance of Amylin, will provide a corporate overview at the Baird conference.
The presentations will be webcast live through the "Investors" section of Amylin's corporate Web site at www.amylin.com, and the recordings will be made available on the Web site following the events. To access the live webcasts, please log on to Amylin's Web site approximately fifteen minutes prior to the presentations to register and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information about Amylin Pharmaceuticals is available at www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.